The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Time is now to get in sub 40. This is likely to go above and beyond very quick. . other major companies waiting for price to crash more will now come out and we may have some sorta bidding war:-))
sold a small position and leaving rest to run. Neve expected this!
Your shorts if u have any. Shire is on fire
Takeda confirms approaching shire. We r up 25%
Shp on Nasdaq preopen points to 4.5% up? Been there on lse earlier, will it come back and sustain it? Paradoxically my broker doesn�t allow shorts on adr. Having long only for couple of weeks, on most contracts, would limit their ability to get panthers loose money, should sp continue this way.Either way rodeo continues...
ZURICH (Reuters) - Roche shares dropped on Wednesday after U.S.-based National Hemophilia Foundation said Roche�s Genentech unit informed it of five deaths of patients treated with its drug Hemlibra. The shares slipped 1.6 percent at 0720 GMT. The foundation quoted Genentech as saying it has limited information about the circumstances surrounding the deaths but that Genentech reported they have �all been deemed unrelated to Hemlibra by the investigator or treating physician�.
*first time poster on Shire, not Roche!*
Long time watcher, first time poster on Roche... There's a story about some deaths of patients taking Hemlibra. Roche share price has dropped
UPDATE 1 � Tokyo court rejects Shire claim against Roche haemophilia drug 08:00 (Adds details of Roche-Shire patent fight) ZURICH, March 28 (Reuters) � A Tokyo court has ruled that Shire's claim against Swiss drugmaker Roche's new Hemlibra haemophilia medicine should be dismissed, Roche's Japanese subsidiary Chugai said on Wednesday, helping to clear up legal uncertainty over the prospective blockbuster medicine. Chugai, which is 60 percent Roche-owned and which developed Hemlibra, said it expected no change to its financial prospects due to the ruling. "Tokyo District Court rendered a decision in favor of Chugai's claim," Chugai said on its website. "(Shire's) claim shall be dismissed in its entirety." Hemlibra is approved in the United States and Europe for patients who have developed resistance, or inhibitors, to standard treatments that include infusions of clotting factors that help stop bleeding in sufferers of haemophilia A. Shire is also seeking a U.S. injunction aimed at stopping some patients from getting Helimbra as it tries to protect its own haemophilia products facing pressure from Roche's new drug. ... Roche is pressing ahead with plans to expand its medicine's approvals to patients who have not developed inhibitors and contends Shire's patent claims are without merit. The patent dispute underscores Hemlibra�s potential to take business from Shire, with some analysts estimating Roche�s roughly $450,000-per-year drug will hit $5 billion in annual sales by muscling in on older drugs for the genetic disease whose sufferers� blood does not clot properly. Shares in Shire have reacted negatively as Hemlibra, also known as ACE910, succeeded in trials ahead of its U.S. Food and Drug Administration approval last year. It was approved this year in Europe. ... (Reporting by John Miller. Editing by Jane Merriman) ((J.Miller@thomsonreuters.com; +41 58 306 7734; Reuters Messaging: j.miller.thomsonreuters.com@reuters.net)
Can you expend on this as I could not find anything about a legal challenge being dismissed?
Mulder, I may have to eat my words if the SP movement is anything to go by. Two days of 100p movements (particularly on a down day like today) is unusual. Unless there is something else driving today's movements, this could be speculative M&A activity.
Why is sp up if our legal challenge just got dismissed???
This is a rarity indeed!
This article offers nothing. He merely says that this company could be on the acquisition radar of other companies. Something that we all know anyway.
Shire seems to be one of those companies where everyone other than the management of the company are aware that below �30 it is fundamentally �too cheap� and that anyway, on a big picture basis, its future should be entwined with a larger international player. Of course, for many large companies these days, the combined business prevention entities of politicians, regulators and the anti-rich squad mean that many a decent deal like GKN gets blown out of the water. However, in the case of Shire it could very well be that it is days, rather than weeks or months, before some M&A developments are forthcoming. On this occasion the company would be mad to protest. At the very least, current share price levels should offer a near term boost despite a falling market. It has been interesting that despite the plunge in stocks, smaller group Vectura (VEC) was up 8%, suggesting that drugs may be regarded a more defensive in a rising interest rate environment.
Mulder, I disagree re bid but completely agree about Ornskov. He is hopeless and in way over his head. If any bid had been made, it would have got out. The fact that the new CFO is buying shares is further proof that there is no ongoing discussions. Potential buyers (if there are any) are playing a wait and see game. If I was thinking of buying Shire, I would want to see out 2018 first to see further proof that the Baxalta purchase has value, that debt repayment continues at same rate (ie profits are reflected in cash and not by accounting manipulation) and the split of the 2 divisions. Given current market conditions, any buyer has plenty of time and may get it cheaper later. Personally I don't think any buyer exists as the risks outweigh the gains. IMO etc
Underperformed the wider market again. Ornskov has done a really poor job IMO. I don't believe that no suitable bid has been made for Shire in the past year - during which time the SP has lost 33% and is now sub-�30. Perhaps he is looking after his own salary and bonuses?
(ShareCast News) - Analysts at Morgan Stanley took a fresh look at rare diseases specialist Shire on Monday, revisiting their bear case as the investment bank reiterated its 'overweight' rating on the group. Morgan Stanley, which snipped its target price on the to 4,700p from its previously issued 5,700p mark, reassessed is bull-bear base values by around 20%, citing setbacks for Lialda generics for the ulcerative colitis drug, challenges for Xiidra's dry-eye market access, threats to the haematology unit, and low visibility on a potential separation of neurosciences, driving a 12% cut to the 2018 consensus EPS forecast. "We also consider different valuation methodologies to gauge a support level for the stock. Our stress test suggests that �29/sh appears to be a floor, slightly above our �27 bear case derived from a less granular approach," Vincent Meunier and his team of analysts said. With the shares changing hands for not much more than 3,000p, analysts' 4,700p price offered a 50% upside and reflected a lower long-term discounted cash flow assumption, even if Shire could still suffer from increased competition in its rare diseases wing, which had so far not been perceived as a risk, as well as the potential of failing to fully integrate Baxalta and extract planned cost synergies from the former Baxter International business. "Shire has undoubtedly suffered from negative newsflow and the overhang of competition. We struggle to justify significant absolute downside from here; the stock remains undervalued and underappreciated for its strong delivery," the Monday note read.
Oh no sorry you are right
Are you sure it is not �32,000? I do not see any dealings that high from a director
Like a stone today . Was hopeful things were starting to settle down .
Nice to see that a Director spent �300k on shares. This is a positive sign in some respect. But it also confirms that there is no takeover activity currently ongoing despite the rumour circulating in the press.
Cant shire be a bit like hikma and Do a 25% plus in 2 days ?
I heard nothing, just a guess how this best might behave. A bit of a wishful thinking too since no more shorts left and filing a bit exposed being long only, don�t count daily �weekly trades. One finger never faraway from hedge, but wouldn�t mind if sp turns a bit positive for a sustainable period.
What news have you heard to make you go long?